HER-2 L755P	HER2 Negative Breast Cancer	HER-2 L755P	HER2 Negative Breast Cancer	trastuzumab + neratinib Sensitive: C3 – Early Trials trastuzumab + neratinib Sensitive : C3	trastuzumab + neratinib Sensitive: C3 – Early Trials trastuzumab + neratinib Sensitive : C3
HER-2 L755P	Non Small Cell Lung Cancer	HER-2 L755P	Non Small Cell Lung Cancer	WZ4002 Sensitive: D – Preclinical WZ4002 Sensitive : D	WZ4002 Sensitive: D – Preclinical WZ4002 Sensitive : D
HER-2 L755P	Non Small Cell Lung Cancer	HER-2 L755P	Non Small Cell Lung Cancer	lapatinib Resistant: D – Preclinical lapatinib Resistant : D	lapatinib Resistant: D – Preclinical lapatinib Resistant : D
HER-2 L755P	Non Small Cell Lung Cancer	HER-2 L755P	Non Small Cell Lung Cancer	CL-387785 Sensitive: D – Preclinical CL-387785 Sensitive : D	CL-387785 Sensitive: D – Preclinical CL-387785 Sensitive : D
HER-2 L755P	Breast Cancer	HER-2 L755P	Breast Cancer	WZ4002 Sensitive: D – Preclinical WZ4002 Sensitive : D	WZ4002 Sensitive: D – Preclinical WZ4002 Sensitive : D
HER-2 L755P	Breast Cancer	HER-2 L755P	Breast Cancer	CL-387785 Sensitive: D – Preclinical CL-387785 Sensitive : D	CL-387785 Sensitive: D – Preclinical CL-387785 Sensitive : D
HER-2 L755P	Non Small Cell Lung Cancer	HER-2 L755P	Non Small Cell Lung Cancer	AEE788 Sensitive: D – Preclinical AEE788 Sensitive : D	AEE788 Sensitive: D – Preclinical AEE788 Sensitive : D

HER-2 L755P

Associations